19
Sep
2024
14:00
BST
09:00
EDT
Webinar
IGHG Recommendations for Coronary Artery Disease Surveillance Among Childhood, Adolescent and Young Adult Cancer Survivors
-
Views:
1305
-
Likes:
10
Overview
Join Dr Elvira C van Dalen (Princess Máxima Center for Pediatric Oncology, NL), Dr Annelies Mavinkurve-Groothuis (Princess Máxima Center for Pediatric Oncology, NL), Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) in this upcoming webinar to discuss recommendations from the International Late Effects of Childhood Cancer Guideline Harmonisation Group (IGHG).
This session will explore critical guidelines for monitoring coronary artery disease in survivors of childhood, adolescent and young adult cancers. Experts will share evidence-based recommendations aimed at improving long-term cardiovascular health outcomes in this vulnerable population. The webinar will provide valuable insights for healthcare professionals involved in survivorship care, with a focus on harmonised global approaches to early detection and prevention of coronary artery disease.
The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.
This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.
Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.
Faculty:
Elvira C van Dalen
Annelies Mavinkurve-Groothuis
Dan Lenihan
Joe Carver
This webinar is supported by
Faculty Biographies
Elvira C van Dalen
Dr Elvira van Dalen, MD PhD, is a senior clinical scientist / epidemiologist and works at the Systematic Review & Guideline Unit of the Princess Máxima Center for Pediatric Oncology, Utrecht, NL. She also is one of the coordinators of the International Late Effects of Childhood Cancer Guideline Harmonisation Group (IGHG).
She did her PhD thesis on anthracycline-induced cardiotoxicity during and after treatment for childhood cancer. Her main research interests are late effects after treatment for childhood cancer, with a special focus on cardiovascular disease and systematic reviews and guidelines in the field of pediatric oncology. She has co-authored over 100 articles in peer-reviewed journals and several book chapters. She is involved in multiple (inter)national studies on cardiotoxicity during and after childhood cancer treatment and in many (inter)national guidelines in collaboration with, among others, the IGHG and the pan-European PanCare network.
Annelies Mavinkurve-Groothuis
Dr Annelies Mavinkurve-Groothuis, MD PhD, is a consultant pediatric oncologist at the Solid Oncology Department and an associate group leader at the Princess Máxima Center for Pediatric Oncology in Utrecht, NL.
She did her PhD thesis on early detection of anthracycline-induced cardiotoxicity in children and survivors with cancer. Part of her research still focuses on the cardiotoxic effects of cancer treatments, both during and after treatment. She is involved in several guidelines of the International Late Effects of Childhood Cancer Guideline Harmonisation Group (IGHG), including the recent dexrazoxane guideline. She is a member of the pediatric group of the International Cardio-Oncology Society (IC-OS).
Dan Lenihan
Dr Dan Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, at Saint Francis Healthcare System, Cape Girardeau, US.
He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
He is actively involved in patient care as the Director of the Cardio-Oncology Programme, Cardiac Rehabilitation, and the Heart Failure clinic at Saint Francis Healthcare System.
Joe Carver
Dr Joe Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, US. He is the Chief of Staff at the Abramson Cancer Center.
He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of cardio-oncology.